Project Grant R43CA250617

This $321,304 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support the development of PDX Pharmaceuticals' nanoparticle-based immunotherapy called ARAC-02 for the treatment of non-small cell lung cancer (NSCLC). The funding will enable two key activities: 1) Pursuing international patent protection for PDX Pharmaceuticals' nanoparticle delivery platform (PDX-NP) and the ARAC-02 product, as well as...

The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $402,402 R21 project grant to the University of Louisville's Office of Research & Innovation. The goal of this 2-year grant, which began on September 19, 2023, is to develop and evaluate a novel tumor glycobiomarker-targeting agent called AVFC Lectibody as a potential immunotherapeutic and diagnostic agent against non-small cell lung cancer (NSCLC). The research aims to assess...

This $424,836 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to characterize and target drug-tolerant persister cells (DTPCs) in small cell lung cancer (SCLC). The project will: 1) Collect and molecularly profile DTPCs from SCLC models and patient samples to track their emergence and trajectory; 2) Assess the ability of a novel SCLC therapy (a bispecific T-cell engager targeting DLL3) to eliminate the post-platinum DTPC population; and 3)...

This federal Project Grant award of $696,569 from the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program supports research by New York University (NYU) School of Medicine to develop novel therapeutic strategies for lung cancer. The key objectives are to: 1) characterize the impact of the protein lipocalin 2 (LCN2) on the tumor microenvironment; 2) develop antibody-based therapies that target LCN2 and assess their efficacy as monotherapy and in combination...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $191,675 to The University of Texas Southwestern Medical Center to investigate the potential of Jumonji lysine demethylases as therapeutic targets for small cell lung cancer (SCLC). The key objectives are to: Evaluate the efficacy of Jumonji inhibitors as first-line therapy for SCLC, including in models resistant to current standard-of-care etoposide chemotherapy. Assess the combination...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Senex Biotechnology Inc. to develop and optimize a nanoparticle formulation of the mediator kinase inhibitor SNX631-6 for intraperitoneal (IP) delivery to treat peritoneal metastatic ovarian cancer. The goal is to increase the efficacy of this drug candidate compared to oral administration through favorable pharmacokinetics and increased tumor accumulation from IP...

This federal Project Grant award of $531,379, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to investigate mitochondrial networks as a critical determinant of response to antibody drug conjugates (ADCs) in advanced/metastatic non-small cell lung cancer (NSCLC). The primary goals of this 5-year study are to: 1) Investigate baseline mitochondrial network architecture as a critical factor influencing NSCLC response to ADCs with the DXD...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $399,970 to Duo Oncology Inc. to develop DUO-207, an ultrasmall nanoparticle formulation designed to improve the delivery and efficacy of combination chemotherapy for advanced pancreatic cancer. The key product being developed under this award is DUO-207, which combines a polymer-conjugated gemcitabine and paclitaxel in a single 14nm nanoparticle. This novel formulation...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Southern California provides $650,450 in funding from July 1, 2025 to June 30, 2030 to develop a novel TCR-engineered CD4+ T cell immunotherapy product for the treatment of lung cancer. The key products and services to be delivered under this award include: 1) Determining the mechanisms by which the MIIC4 TCRM50A-STEM2 T cell product eliminates lung cancer...